The history of the Gyrolab platform

More than 20 years ago, we introduced the groundbreaking Gyrolab CD-based technology at DDT in Boston. Today, our proprietary high-performance nanoliter-scale immunoassay platforms, Gyrolab xPand and Gyrolab xPlore, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies worldwide.

Applications include bioanalytical pharmacokinetics/pharmacodynamics, immunogenicity, biomarkers, and for bioprocess, affinity, product titer and quantitation of bioprocess-related impurities.

Our Innovation Timeline

history-1988-1999

1988-1999

Amersham Pharmacia Biotech

Project on miniaturization and microfluidics.

1988-1999

2000

Gyros AB formed

Spin off from Amersham Pharmacia Biotech.

2000

2002

Gyrolab Maldi SP1

First instrument for purifying protein samples for analysis by MALDI MS.

2002

2003

Gyrolab Workstation and Bioaffy 200 CD

First immunoassay system for nanoliter-scale protein quantification launched at DDT in Boston.

2003

2006

Cambridge Antibody Technologies purchases first system

Now Medimmune, Cambridge Antibody Technologies purchases first system for use in biotherapeutic development. Download Case Study: "One Mouse, One PK... the Magic of Capillary Microsampling and Gyrolab."

2006

Gyrolab xP open

2009

Gyrolab xP launched

5-CD Gyrolab xP system launched with software designed for 21 CFR Part 11 compliance and extended validation support.

2009

2011

Launch of ADA Solution

New Mixing CD 96 and software for analysis of anti-drug antibodies in serum for preclinical and clinical studies.

2011

2014

Gyrolab Protein A Kit launched

Gyrolab Protein A Kit launched for detection of Protein A ligand impurities in bioprocess samples.

2014

2015

Launch of Gyrolab xPlore system

Compact, precise, single disc alternative ready for development and QC. Combined with expanded kit support for IgG titer and CHO host cell proteins.

2015

2016

Gyrolab Affinity Software launched

Gyrolab Affinity Software module launched for in-solution affinity measurement.

2016

Gyros Protein Technologies formed

Gyros Protein Technologies was formed by the merger of Gyros AB and Protein Technologies, Inc., expanding offerings with the peptide synthesizers product line.

2017

Expanding with more bioanalysis tools

Inclusion of a generic PK kit for monitoring circulating therapeutic antibodies and a dedicated solution for anti-drug- antibody (ADA) complex detection.

2017

2018

Launch of Gyrolab xPand

Cooling of samples and reagents
Mix and match methods/CDs in a single run

2018

2019

Extended impurity and titer offering

Expanding into cell and gene therapy segment with the Gyrolab p24 Kit for lentiviral quantification — and supporting HCP impurity testing using proprietary antibodies with the Gyrolab® Bioaffy™ 1000HC Assay Toolbox.

2019

Acquisition of Gyros Protein Technologies by Mesa Laboratories, Inc. in 2019

Acquisition of Gyros Protein Technologies by Mesa Laboratories, Inc.

Gyros Protein Technologies is now a Division of Mesa Laboratories, Inc.

2020

Expanded CGT titer kit menu and tools for impurity testing

Two new additions to the Gyrolab portfolio, a AAV titer kit which quantifies eight common AAV capsid serotypes, and the Bioaffy™ 1000 HC disc, designed for improved assay performance with reagents of low affinity.

2020

2021

High-sensitivity immunoassay and impurity testing using gold-standard antibodies are enabled

Expands portfolio with the Gyrolab Bioaffy™ 4000 CD and ready-to-use solutions developed in collaboration with Cygnus Technologies, Inc.

2021

2022

Kits for cytokine biomarker testing and buffer screening launched

Portfolio expanded with the Rexxip™ Scouting Pack for faster buffer screening in assay development, and a new category of human cytokine kit reagents delivering quantification of biomarkers to low pg/mL levels, helping labs move faster with less hands-on time.

2022

Gyrolab 2G Generic PK Kit Reagents

2023

Gyrolab technology celebrates 20 years of innovation

With expanded kit options that improve sensitivity for quantifying circulating therapeutic antibodies (PK) and circulating immune complexes (ADA, and support safer, more efficient monoclonal antibody development (PLBL2 impurities).

Further expansion into biomarker and immunogenicity testing

Gyrolab now supports the quantification of cytokines in preclinical models and testing of immunogenicity in mAb- and AAV-based programs.

Extended host cell protein impurity testing offering

Kits for quantifying host cell proteins from HEK293 cell lines, developed in collaboration with BioGenes GmbH, extend the coverage of Gyrolab kits for CGT development workflows.

2023

2024 kit launches

2024

Launch of new Gyrolab immunogenicity and biomarker Kits

Gyrolab Mouse Cytokine Kits
For quantification of murine TNF-alpha, IFN-gamma, IL-6, IL-10, and IL-4. Sensitive, robust, and automated assays.

Gyrolab Generic Rodent ADA Kit Reagents
For the detection of circulating immune complexes of human IgG therapeutic with rodent (mouse or rat) anti-human IgG ADAs.

Gyrolab Generic Anti-AAV Kit
Gyrolab Generic Anti-AAV Kit enables detection of anti-AAV antibodies in human and cynomolgus monkey matrices.

2024

Gyrolab HEK293 HCP Kits

2025

Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to support biotherapeutic development

Developed with antibodies from BioGenes GmbH, a global leader in host cell protein (HCP) assay development, the new kits enable rapid detection of HCPs from HEK293 cell lines.

2025